Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ligand Pharmaceuticals Inc.
Headquarters: Jupiter, FL, United States of America
Website: http://www.ligand.com
Year Founded: 1987
Status: Public
Industry Sector: HealthTechnology
CEO: Todd C. Davis, MBA
Number Of Employees: 68
Enterprise Value: $1,710,713,500
PE Ratio: -646.56
Exchange/Ticker 1: NASDAQ:LGND
Exchange/Ticker 2: N/A
Latest Market Cap: $1,917,260,288
BioCentury | Oct 18, 2024
Management Tracks
Hoess succeeds Crawford at ViaNautis
Plus: Korenberg now CFO of Palvella and updates from Moffitt and CHMP
BioCentury | May 14, 2024
Deals
Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines
Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more
BioCentury | Apr 4, 2024
Management Tracks
Upstream names new CEO, CFO and COO
Plus: Acadia hires Elizabeth Thompson as head of R&D, and updates from Insitro, Fractyl, Adarx and more
BioCentury | Apr 3, 2024
Data Byte
Last minute flurry brings FDA’s first-quarter NME approvals to 10
Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive
BioCentury | Mar 13, 2024
Data Byte
NME approvals off to slow start in 2024
FDA has approved just three NMEs so far this year, down from 10 at this time in 2023
BioCentury | Feb 17, 2024
Management Tracks
Agresta joining OnKure as CMO
Plus: Viridian hires Tousignant and an update from Ligand
BioCentury | Jan 6, 2024
Data Byte
10 more PDUFA dates in January following year’s first FDA approval
Upcoming decisions include Astellas’ zolbetuximab, the first CLDN18.2 mAb up for approval
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Aug 7, 2023
Management Tracks
Khoo Shih named CEO of Singapore’s ClavystBio
Plus: New CEOs named at Vivoryon and Kytopen, and updates from Avalyn, Ankyra, Indaptus and more
BioCentury | Feb 7, 2023
BioCentury Commentary
Big thinkers
Pharma mega-mergers — a look back at the rationale behind the Glaxo-SmithKline tie-up: BioCentury’s 30th anniversary collection
Items per page:
1 - 10 of 802